{
    "nctId": "NCT00065325",
    "briefTitle": "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer",
    "officialTitle": "A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX\u2122) vs. Exemestane (AROMASIN\u2122) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 694,
    "primaryOutcomeMeasure": "Time to disease progression (TTP)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy confirmation of Breast Cancer\n* Breast Cancer has continued to grow after having received treatment with an aromatase inhibitor\n* Postmenopausal women defined as a women who has stopped having menstrual periods\n* Evidence of hormone sensitivity\n* Written informed consent to participate in the trial\n\nExclusion Criteria:\n\n* Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)\n* Any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor\n* Treatment with an investigational or non-approved drug within one month\n* An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures\n* A history of allergies to any active or inactive ingredients of Faslodex or Exemestane (i.e. castor oil or Mannitol)",
    "sex": "FEMALE",
    "minimumAge": "32 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}